Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced an update of the ProSTAR study, its ongoing Phase 1b/2 clinical trial of CPI-1205 in patients with metastatic castration-resistant prostate cancer (mCRPC). As quoted in the press release: The ProSTAR study is evaluating CPI-1205, Constellation’s potent and … Continued
The post Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients appeared first on Investing News Network.